Australian healthcare company Stirling Products (STI) is pleased to advise that the key study results of this recent trial confirmed a complete cure of all XDR TB patients supplemented with the botanical immunotherapy product, Immunoxel which demonstrated 100% effectiveness and reduced treatment duration to less than 4 months in all patients as opposed to the general 18-24 months of treatment with standard TB drugs.
Mr. Volodymyr Pylypchuk Director of Ekomed, the product licensor said, “The immune intervention developed by us can not only shorten treatment time and costs drastically but also save countless lives. Our study conducted in Ukraine shows that we can offer a practical solution to the current global TB crisis. We are now planning independent studies in Asia and Africa with the specific aim to use much larger patient population which will support our findings.”
